Retinal Disease Research
Eyebiotech Limited focuses on clinical research in diabetic macular edema, with an emphasis on treatment approaches for vision loss linked to retinal vascular disease and macular swelling.
- Diabetic macular edema
- Retinal pathology
- Macular edema
The sponsor’s trial activity is centred on ophthalmic outcomes relevant to central vision and retinal health.
Ophthalmology and Vision Care
The sponsor supports studies in ophthalmology that evaluate therapies intended to preserve or improve best-corrected visual acuity in patients with diabetic eye disease.
- Best-corrected visual acuity
- Visual function
- Diabetic eye disease
This area reflects a clear interest in clinical endpoints tied to sight-threatening retinal conditions.
Anti-VEGF Therapeutics
Eyebiotech Limited is engaged in research on anti-vascular endothelial growth factor treatment strategies, including intravitreal approaches for retinal disorders associated with fluid accumulation and impaired vision.
- Anti-VEGF therapy
- Intravitreal treatment
- Vascular endothelial growth factor inhibition
The sponsor’s therapeutic interest is directed toward agents used in chronic retinal disease management.
Clinical Ophthalmic Outcomes
Its research activity places attention on measurable eye-care outcomes such as ETDRS visual acuity assessment and changes in central retinal function over time.
- ETDRS chart assessment
- Visual acuity endpoints
- Retinal function
These interests align with clinical evaluation of therapies for diseases affecting the macula and central vision.
